Malagrinò Francesca, Puglisi Elena, Pagano Livia, Travaglini-Allocatelli Carlo, Toto Angelo
Dipartimento di Medicina Clinica, Sanità Pubblica, Scienze Della Vita e Dell'ambiente, Universita' Dell'Aquila, Piazzale Salvatore Tommasi 1, L'Aquila, Coppito, 67010, Italy.
Dipartimento di Scienze Biochimiche "A. Rossi Fanelli", Sapienza Universita di Roma, P.le Aldo Moro 5, 00185, Rome, Italy - Laboratory Affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Italy.
Biochem Biophys Rep. 2024 Jul 29;39:101803. doi: 10.1016/j.bbrep.2024.101803. eCollection 2024 Sep.
GRB2, or Growth Factor Receptor-Bound Protein 2, is a pivotal adaptor protein in intracellular signal transduction pathways, particularly within receptor tyrosine kinase (RTK) signaling cascades. Its crystal structure reveals a modular architecture comprising a single Src homology 2 (SH2) domain flanked by two Src homology 3 (SH3) domains, facilitating dynamic interactions critical for cellular signaling. While SH2 domains recognize phosphorylated tyrosines, SH3 domains bind proline-rich sequences, enabling GRB2 to engage with various downstream effectors. Folding and binding studies of GRB2 in its full-length form and isolated domains highlight a complex interplay between its protein-protein interaction domains on the folding energy landscape and in driving its function. Being at the crosslink of many key molecular pathways in the cell, GRB2 possesses a role in cancer pathogenesis, particularly in mediating the Ras-mitogen activated protein kinase (MAPK) pathway. Thus, pharmacological targeting of GRB2 domains is a promising field in cancer therapy, with efforts focused on disrupting protein-protein interactions. However, the dynamic interplay driving GRB2 function suggests the presence of allosteric sites at the interface between domains that could be targeted to modulate the binding properties of its constituent domains. We propose that the analysis of GRB2 proteins from other species may provide additional insights to make the allosteric pharmacological targeting of GRB2 a more feasible strategy.
GRB2,即生长因子受体结合蛋白2,是细胞内信号转导通路中的关键衔接蛋白,尤其是在受体酪氨酸激酶(RTK)信号级联反应中。其晶体结构显示出一种模块化结构,由一个Src同源2(SH2)结构域和两侧的两个Src同源3(SH3)结构域组成,有助于细胞信号传导所需的动态相互作用。SH2结构域识别磷酸化酪氨酸,而SH3结构域结合富含脯氨酸的序列,使GRB2能够与各种下游效应器相互作用。对全长GRB2及其分离结构域的折叠和结合研究突出了其蛋白质 - 蛋白质相互作用结构域在折叠能量景观和驱动其功能方面的复杂相互作用。由于处于细胞中许多关键分子通路的交叉点,GRB2在癌症发病机制中发挥作用,特别是在介导Ras - 丝裂原活化蛋白激酶(MAPK)通路方面。因此,针对GRB2结构域的药物靶向是癌症治疗中一个有前景的领域,目前的努力集中在破坏蛋白质 - 蛋白质相互作用上。然而,驱动GRB2功能的动态相互作用表明,在结构域之间的界面处存在变构位点,可以靶向这些位点来调节其组成结构域的结合特性。我们认为,对其他物种的GRB2蛋白进行分析可能会提供更多见解,使GRB2的变构药物靶向成为一种更可行的策略。